Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

971.26 -0.99 (-0.10%)
Streaming Delayed Price Updated: 3:42 PM EDT, Sep 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
From argenx SE
Via GlobeNewswire
News headline image
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx Completes Acquisition of Forte Biosciences, Inc.
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
From argenx SE
Via GlobeNewswire
News headline image
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
From Forte Biosciences, Inc.
Via Business Wire
News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx to Host Autoimmune Myositis R&D Webinar
From argenx SE
Via GlobeNewswire
News headline image
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx to Host Myositis R&D Webinar on June 23, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at BofA Securities 2026 Health Care Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
From argenx SE
Via GlobeNewswire
News headline image
argenx announces Annual General Meeting of Shareholders on May 6, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at TD Cowen 46th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx Highlights 2026 Strategic Priorities
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.